分红方面，华人健康A股上市后累计派现8000.20万元。 融券方面，华人健康12月10日融券偿还0.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00 元；融券余量100.00股，融券余额1579.00元，超过近一年60%分位水平，处于较高位。 资料显示，安徽华人健康医药股份有限公司位于安徽省合肥市河北路123号A1栋，成立日期2001年6月 29日，上市日期2023年3月1日，公司主营业务涉及主要从事医药代理、零售及终端集采三大块业务。主 营业务收入构成为：中西成药97.60%，其他(补充)2.40%。 截至9月30日，华人健康股东户数2.01万，较上期减少22.86%；人均流通股7422股，较上期增加 29.64%。2025年1月-9月，华人健康实现营业收入38.92亿元，同比增长19.06%；归母净利润1.57亿元， 同比增长45.21%。 来源：新浪证券-红岸工作室 12月10日，华人健康涨1.54%，成交额3.73亿元。两融数据显示，当日华人健康获融资买入额2692.86万 元，融资偿还4651.78万元，融资净买入-1958.92万元。截至12月10日，华人健康融资融券余额合计1.32 ...

Group 1 - Cambridge Technology plans to invest 400 million yuan to establish a fund focused on optical devices and chips, aiming to invest in early-stage and growth-stage companies in the hard technology sector [1] - Tunnel Corporation's consortium won a bid for a highway project in Henan with a total investment of 6.49 billion yuan, using a BOT model for a 33.25-year cooperation period [2] - Hongrun Construction won a bid for a project worth 230 million yuan, which represents 3.88% of the company's projected revenue for 2024 [3] Group 2 - Tongrentang's product, Canling Baizhu Powder, received product registration approval from Health Canada, aimed at treating symptoms related to spleen and stomach weakness [4] - Hunan Baiyin announced a scheduled annual maintenance from December 9, 2025, to January 5, 2026, for equipment and facilities [5] - Changchun Gaoxin's subsidiary had two drugs included in the national medical insurance catalog for 2025 [6] Group 3 - Dongfang Securities' chairman resigned due to work relocation [7] - Xuantai Pharmaceutical's product, Sitagliptin Metformin Sustained-Release Tablets, was renewed for inclusion in the national medical insurance catalog [8] - ST Weihai was pre-selected for a smart agriculture EPC project with a bid of 652 million yuan, accounting for 26.27% of the company's projected revenue for 2024 [9] Group 4 - Guoxin Technology successfully tested an anti-quantum password financial POS chip, supporting both traditional and quantum-resistant algorithms [10] - Huaren Health's subsidiary received acceptance for a drug registration application for Lactulose Oral Solution, a common laxative [11] - Ankai Bus reported a 57.71% year-on-year increase in sales for the first 11 months of the year [12] Group 5 - Zhongyan Dadi's subsidiary won a bid for a project worth 73.86 million yuan [13] - Zhejiang Rongtai plans to invest 77 million USD in a factory in Thailand, focusing on mica paper and robot components production [14] - Optoelectronics plans to use up to 450 million yuan of idle funds for cash management [15] Group 6 - Tianyu Biological reported a 45.15% year-on-year decline in sales revenue from pig sales in November [16] - Daqin Railway's cargo transport volume increased by 1.75% year-on-year in November [17] - Yabo Co. won a bid for a heavy truck charging station project worth 3.616 million yuan [18] Group 7 - Hongri Pharmaceutical's product continues to be included in the national medical insurance catalog [19] - Jinggong Steel Structure signed a contract for steel structure installation worth approximately 470 million yuan for an overseas project [20] - Xizang Pharmaceutical's product, Xinhuasuan, continues to be included in the national medical insurance catalog [21] Group 8 - Guangdong Electric Power A announced the successful commissioning of a 1000MW unit at the Maoming Boge Power Plant [22] - Fuan Pharmaceutical's product, Palivizumab Injection, was newly included in the national medical insurance catalog [23] - Lizhu Group reported that 194 products were included in the 2025 national medical insurance catalog [24] Group 9 - Haisan Pharmaceutical's injection of Lantanol was included in the national medical insurance catalog [25] - Zhongtong Bus reported a 39.53% year-on-year increase in sales volume in November [26] - Shaanxi Coal Industry reported a 6.03% year-on-year increase in coal production in November [27] Group 10 - Haooubo's subsidiary received a medical device registration certificate for an IgG4 testing kit [28] - Yaopi Glass plans to invest 690 million yuan in new automotive glass production lines [30] - Huadian International completed the issuance of 2 billion yuan in medium-term notes [31] Group 11 - Zhongzai Zihuan's subsidiary won a bid for a green recycling project worth 205 million yuan [32] - Dabeinong reported a 25.26% year-on-year decline in sales revenue from pig sales in November [33] - Xiangjia Co. reported a 3.77% year-on-year increase in live poultry sales revenue in November [34] Group 12 - Huanxu Electronics reported a consolidated revenue of 5.198 billion yuan in November, a decrease of 3.34% year-on-year [35] - Aonong Biological reported a 72.21% year-on-year increase in pig sales volume in November [36] - Samsung Medical's subsidiary was pre-selected for a procurement project worth approximately 108 million yuan [37]

Core Viewpoint - The company, Huaren Health (301408.SZ), has received a drug registration acceptance notice from the National Medical Products Administration for its oral solution of lactulose, indicating a significant step towards market entry for this laxative product [1]. Group 1: Product Information - The lactulose oral solution is a commonly used laxative for treating constipation, known for its ability to soften stools and regulate intestinal rhythm [1]. - Key characteristics of the product include rapid and gentle efficacy, along with high safety, making it suitable for long-term use by individuals with chronic or habitual constipation [1].

Core Viewpoint - The company, Huaren Health, has received a drug registration acceptance notice from the National Medical Products Administration for its oral solution of lactulose, indicating a significant step towards market entry for this commonly used laxative [1] Group 1: Company Developments - Huaren Health's wholly-owned subsidiary, Jiangsu Shenhua Pharmaceutical Co., Ltd., has been granted the acceptance notice for the lactulose oral solution [1] - The lactulose oral solution is characterized by its quick and gentle laxative effect, high safety profile, and suitability for long-term use in patients with chronic or habitual constipation [1] Group 2: Industry Insights - Lactulose is a commonly used medication for treating constipation, known for its ability to soften stools and regulate intestinal function [1] - The product's features make it particularly appealing for a demographic that requires effective and safe long-term treatment options for constipation [1]

Group 1 - The core viewpoint is that Alibaba Health Technology has been a strategic investor in the company since May 2018 and continues to be one of the top ten shareholders as of September 30, 2025 [1] - The company collaborates with Alibaba Health and its associated platforms, including Alipay, Tmall, and Ele.me, to enhance its operational capabilities [1] - The company emphasizes that all operational information is disclosed through official announcements on the Giant Tide Information Network [1]

Core Viewpoint - The company Huaren Health (301408.SZ) has received a drug registration acceptance notice from the National Medical Products Administration for its oral solution of lactulose, indicating a significant step towards market entry for this commonly used laxative [1] Group 1: Product Overview - The lactulose oral solution is a laxative used for treating constipation, known for its ability to soften stools and regulate intestinal rhythm [1] - Key characteristics of lactulose include rapid and gentle efficacy, high safety, and suitability for long-term use in chronic or habitual constipation patients [1] Group 2: Mechanism of Action - Lactulose is metabolized in the colon by gut flora into organic acids, leading to a decrease in intestinal pH [1] - This process retains water and increases stool volume, stimulating colonic peristalsis, maintaining stool passage, alleviating constipation, and restoring the physiological rhythm of the colon [1]

Core Viewpoint - The company Huaren Health (301408.SZ) has received a registration acceptance notice from the National Medical Products Administration for its oral solution of lactulose, indicating a significant step towards market entry for this commonly used laxative [1] Group 1: Product Overview - The lactulose oral solution is a laxative that is commonly used to treat constipation, characterized by its ability to soften stools and regulate intestinal rhythm [1] - The product is noted for its quick and gentle effect, high safety profile, and suitability for long-term use in individuals with chronic or habitual constipation [1] Group 2: Mechanism of Action - Lactulose is metabolized in the colon by gut flora into organic acids, which lowers the pH in the intestines and retains water, thereby increasing stool volume [1] - This mechanism stimulates colonic peristalsis, ensuring smooth bowel movements and alleviating constipation while restoring the physiological rhythm of the colon [1]

Core Viewpoint - The company announced that its wholly-owned subsidiary, Jiangsu Shenhua Pharmaceutical Co., Ltd., has received the acceptance notice for the registration application of Lactulose Oral Solution from the National Medical Products Administration, indicating the product has entered the registration review stage [1] Group 1: Product Details - Lactulose Oral Solution is a laxative characterized by its quick, gentle, and effective action, with high safety, making it suitable for individuals with chronic or habitual constipation [1] Group 2: Regulatory Process - The acceptance of the drug registration application signifies that the product is now in the registration review phase, with completion time, approval results, and post-approval sales conditions remaining uncertain [1] Group 3: Financial Impact - The company stated that the registration application will not have a significant impact on its short-term performance [1]

证券代码：301408 证券简称：华人健康 公告编号：2025-073 安徽华人健康医药股份有限公司 关于全资子公司收到药品注册受理通知书的公告 申请事项：境内生产药品注册上市许可 产品名称：乳果糖口服溶液 规格：15ml:10g 受理说明：根据《中华人民共和国行政许可法》第三十二条的规定，经审查， 决定予以受理。 受理号：CYHS250***8 二、乳果糖口服溶液的相关情况 乳果糖口服溶液是一种缓泻药，是治疗便秘的常用药，具有软化大便和调节 肠道规律的作用，主要特点是通便起效快、温和有效，安全性高，适合长期慢性 或习惯性便秘人群使用。 乳果糖在结肠中被消化道菌丛转化成有机酸，导致肠道内 pH 值下降，并通 过保留水分，增加粪便体积。上述作用刺激结肠蠕动，保持大便通畅，缓解便秘， 同时恢复结肠的生理节律。 本公司及董事会全体成员保证信息披露内容真实、准确和完整，不存在任何 虚假记载、误导性陈述或者重大遗漏。 近日，安徽华人健康医药股份有限公司（以下简称"公司"）全资子公司江 苏神华药业有限公司收到国家药品监督管理局下发的乳果糖口服溶液药品注册 上市许可申请《受理通知书》。现将相关情况公告如下： 一、《受理通知 ...

来源：新浪证券-红岸工作室 12月5日，华人健康涨1.15%，成交额6.56亿元。两融数据显示，当日华人健康获融资买入额9084.95万 元，融资偿还6612.12万元，融资净买入2472.83万元。截至12月5日，华人健康融资融券余额合计1.83亿 元。 截至9月30日，华人健康股东户数2.01万，较上期减少22.86%；人均流通股7422股，较上期增加 29.64%。2025年1月-9月，华人健康实现营业收入38.92亿元，同比增长19.06%；归母净利润1.57亿元， 同比增长45.21%。 分红方面，华人健康A股上市后累计派现8000.20万元。 机构持仓方面，截止2025年9月30日，华人健康十大流通股东中，香港中央结算有限公司位居第五大流 通股东，持股232.03万股，相比上期增加133.57万股。 融资方面，华人健康当日融资买入9084.95万元。当前融资余额1.83亿元，占流通市值的7.32%，融资余 额超过近一年90%分位水平，处于高位。 融券方面，华人健康12月5日融券偿还0.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00元； 融券余量0.00股，融券余额0.00元，低于近 ...